发明名称 Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
摘要 The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. <CHEM> In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula -CO-, etc.; X indicates a single bond, an oxygen atom etc.; R<1> indicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D<1>, D<2>, W<1> and W<2> are the same as or different from each other and each represents a single bond or an optionally substituted C1-6 alkylene chain.
申请公布号 AU2705901(A) 申请公布日期 2001.07.31
申请号 AU20010027059 申请日期 2001.01.18
申请人 EISAI CO. LTD. 发明人 NOBORU YAMAMOTO;YUICHI SUZUKI;MANAMI KIMURA;TETSUHIRO NIIDOME;YOICHI IIMURA;TETSUYUKI TERAMOTO;YOSHIHISA KANEDA;TOSHIHIKO KANEKO;NOBUYUKI KURUSU;DAISUKE SHINMYO;YUKIE YOSHIKAWA;SHINJI HATAKEYAMA
分类号 A61K31/395;A61P9/10;C07D207/09;C07D207/14;C07D207/16;C07D207/32;C07D207/337;C07D209/14;C07D209/42;C07D211/22;C07D211/26;C07D211/32;C07D211/34;C07D211/46;C07D211/58;C07D211/64;C07D213/36;C07D213/38;C07D213/57;C07D213/74;C07D215/06;C07D215/12;C07D215/22;C07D215/227;C07D215/38;C07D217/04;C07D217/22;C07D235/10;C07D235/14;C07D235/30;C07D241/04;C07D243/08;C07D261/08;C07D263/20;C07D263/32;C07D263/58;C07D271/06;C07D277/28;C07D277/42;C07D277/82;C07D295/14;C07D295/145;C07D295/185;C07D295/192;C07D295/215;C07D307/52;C07D307/54;C07D307/81;C07D319/20;C07D333/24;C07D333/28;C07D333/38;C07D333/60;C07D401/04;C07D401/06;C07D401/12;C07D403/04;C07D405/06;C07D409/00;C07D409/06;C07D409/12;C07D409/14;C07D413/04;C07D413/12;C07D413/14;C07D417/04;C07D417/08;C07D417/12;C07D471/10;C07D487/08 主分类号 A61K31/395
代理机构 代理人
主权项
地址